Silencing of endogenous IL-10 in human dendritic cells leads to the generation of an improved CTL response against human melanoma associated antigenic epitope, MART-127-35

Clinical Immunology

Volumn 126, Issue 3, 2008, Pages 251-259

  Chhabra, Arvind ^a   Chakraborty, Nitya G ^a   Mukherji, Bijay ^a  

^a UNIVERSITY OF CONNECTICUT SCHOOL OF MEDICINE   (United States)

Author keywords

Adenovirus; Cytotoxic T lymphocytes (CTL); Dendritic cells (DC); Interleukin 10 (IL 10)

Indexed keywords

EPITOPE; GREEN FLUORESCENT PROTEIN; INTERLEUKIN 10; INTERLEUKIN 12; LIPID; MELAN A; MELAN A[27-35]; MELANOMA ANTIGEN; RNA ANTIBODY; SMALL INTERFERING RNA; UNCLASSIFIED DRUG;

ADENOVIRUS; ANTIGEN PRESENTATION; ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; GENE SILENCING; GENETIC TRANSCRIPTION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNOGENICITY; NONHUMAN; PRIORITY JOURNAL; RNA INTERFERENCE; T LYMPHOCYTE ACTIVATION; TH1 CELL; TH2 CELL; VIRUS RECOMBINANT;

CELL LINE, TUMOR; DENDRITIC CELLS; EPITOPES; GENE SILENCING; GREEN FLUORESCENT PROTEINS; HUMANS; INTERLEUKIN-10; INTERLEUKIN-12; MELANOMA; NEOPLASM PROTEINS; RNA, SMALL INTERFERING; T-LYMPHOCYTES, CYTOTOXIC; UP-REGULATION;

EID: 39149144795     PISSN: 15216616     EISSN: 15217035     Source Type: Journal    
DOI: 10.1016/j.clim.2007.11.011     Document Type: Article

References (35)

1. Banchereau J., and Steinman R.M. Dendritic cells and the control of immunity. Nature 392 6673 (1998) 245
2. Banchereau J., Fay J., Paczesny S., Ueno H., Dhodapkarz M., and Palucka A.K. Dendritic cells as melanoma vaccines. Dev. Biol. (Basel) 116 (2004) 147
3. Maldonado-Lopez R., and Moser M. Dendritic cell subsets and the regulation of Th1/Th2 responses. Semin. Immunol. 13 5 (2001) 275
4. Moser M., and Murphy K.M. Dendritic cell regulation of TH1-TH2 development. Nat. Immunol. 1 3 (2000) 199
5. Chakraborty A., Li L., Chakraborty N.G., and Mukherji B. Stimulatory and inhibitory maturation of human macrophage-derived dendritic cells. Pathobiology 67 5-6 (1999) 282
6. Chakraborty A., Li L., Chakraborty N.G., and Mukherji B. Stimulatory and inhibitory differentiation of human myeloid dendritic cells. Clin. Immunol. 94 2 (2000) 88
7. Corinti S., Albanesi C., la Sala A., Pastore S., and Girolomoni G. Regulatory activity of autocrine IL-10 on dendritic cell functions. J. Immunol. 166 7 (2001) 4312
8. Willems F., Marchant A., Delville J.P., Gerard C., Delvaux A., Velu T., de Boer M., and Goldman M. Interleukin-10 inhibits B7 and intercellular adhesion molecule-1 expression on human monocytes. Eur. J. Immunol. 24 4 (1994) 1007
9. Allavena P., Piemonti L., Longoni D., Bernasconi S., Stoppacciaro A., Ruco L., and Mantovani A. IL-10 prevents the generation of dendritic cells from CD14+ blood monocytes, promotes the differentiation to mature macrophages and stimulates endocytosis of FITC-dextran. Adv. Exp. Med. Biol. 417 (1997) 323
10. De Smedt T., Van Mechelen M., De Becker G., Urbain J., Leo O., and Moser M. Effect of interleukin-10 on dendritic cell maturation and function. Eur. J. Immunol. 27 5 (1997) 1229
11. Liu L., Rich B.E., Inobe J., Chen W., and Weiner H.L. Induction of Th2 cell differentiation in the primary immune response: dendritic cells isolated from adherent cell culture treated with IL-10 prime naive CD4+ T cells to secrete IL-4. Int. Immunol. 10 8 (1998) 1017
12. Letterio J.J., and Bottinger E.P. TGF-beta knockout and dominant-negative receptor transgenic mice. Miner. Electrolyte Metab. 24 2-3 (1998) 161
13. Marques J.T., and Williams B.R. Activation of the mammalian immune system by siRNAs. Nat. Biotechnol. 23 11 (2005) 1399
14. Hill J.A., Ichim T.E., Kusznieruk K.P., Li M., Huang X., Yan X., Zhong R., Cairns E., Bell D.A., and Min W.P. Immune modulation by silencing IL-12 production in dendritic cells using small interfering RNA. J. Immunol. 171 2 (2003) 691
15. Liu G., Ng H., Akasaki Y., Yuan X., Ehtesham M., Yin D., Black K.L., and Yu J.S. Small interference RNA modulation of IL-10 in human monocyte-derived dendritic cells enhances the Th1 response. Eur. J. Immunol. 34 6 (2004) 1680
16. Zamore P.D., Tuschl T., Sharp P.A., and Bartel D.P. RNAi: double-stranded RNA directs the ATP-dependent cleavage of mRNA at 21 to 23 nucleotide intervals. Cell 101 1 (2000) 25
17. Elbashir S.M., Lendeckel W., and Tuschl T. RNA interference is mediated by 21- and 22-nucleotide RNAs. Genes Dev. 15 2 (2001) 188
18. McManus M.T., Haines B.B., Dillon C.P., Whitehurst C.E., van Parijs L., Chen J., and Sharp P.A. Small interfering RNA-mediated gene silencing in T lymphocytes. J. Immunol. 169 10 (2002) 5754
19. Sui G., Soohoo C., Affar el B., Gay F., Shi Y., and Forrester W.C. A DNA vector-based RNAi technology to suppress gene expression in mammalian cells. Proc. Natl. Acad. Sci. U. S. A. 99 8 (2002) 5515
20. Shen C., Buck A.K., Liu X., Winkler M., and Reske S.N. Gene silencing by adenovirus-delivered siRNA. FEBS Lett. 539 1-3 (2003) 111
21. Tiscornia G., Singer O., Ikawa M., and Verma I.M. A general method for gene knockdown in mice by using lentiviral vectors expressing small interfering RNA. Proc. Natl. Acad. Sci. U. S. A. 100 4 (2003) 1844
22. Zhai Y., Yang J.C., Kawakami Y., Spiess P., Wadsworth S.C., Cardoza L.M., Couture L.A., Smith A.E., and Rosenberg S.A. Antigen-specific tumor vaccines. Development and characterization of recombinant adenoviruses encoding MART1 or gp100 for cancer therapy. J. Immunol. 156 2 (1996) 700
23. Chhabra A., Mehrotra S., Chakraborty N.G., Mukherji B., and Dorsky D.I. Cross-presentation of a human tumor antigen delivered to dendritic cells by HSV VP22-mediated protein translocation. Eur. J. Immunol. 34 10 (2004) 2824
24. Mehrotra S., Chhabra A., Chattopadhyay S., Dorsky D.I., Chakraborty N.G., and Mukherji B. Rescuing melanoma epitope-specific cytolytic T lymphocytes from activation-induced cell death, by SP600125, an inhibitor of JNK: implications in cancer immunotherapy. J. Immunol. 173 10 (2004) 6017
25. Mehrotra S., Chhabra A., Chakraborty A., Chattopadhyay S., Slowik M., Stevens R., Zengou R., Mathias C., Butterfield L.H., Dorsky D.I., Economou J.S., Mukherji B., and Chakraborty N.G. Antigen presentation by MART-1 adenovirus-transduced interleukin-10-polarized human monocyte-derived dendritic cells. Immunology 113 4 (2004) 472
26. Chhabra A., Mehrotra S., Chakraborty N.G., Dorsky D.I., and Mukherji B. Activation-induced cell death of human melanoma specific cytotoxic T lymphocytes is mediated by apoptosis-inducing factor. Eur. J. Immunol. 36 12 (2006) 3167
27. Nouri-Shirazi M., Banchereau J., Fay J., and Palucka K. Dendritic cell based tumor vaccines. Immunol. Lett. 74 1 (2000) 5
28. Yee C., Thompson J.A., Byrd D., Riddell S.R., Roche P., Celis E., and Greenberg P.D. Adoptive T cell therapy using antigen-specific CD8+ T cell clones for the treatment of patients with metastatic melanoma: in vivo persistence, migration, and antitumor effect of transferred T cells. Proc. Natl. Acad. Sci. U. S. A. 99 25 (2002) 16168
29. Mukherji B., Chakraborty N.G., Yamasaki S., Okino T., Yamase H., Sporn J.R., Kurtzman S.K., Ergin M.T., Ozols J., Meehan J., et al. Induction of antigen-specific cytolytic T cells in situ in human melanoma by immunization with synthetic peptide-pulsed autologous antigen presenting cells. Proc. Natl. Acad. Sci. U. S. A. 92 17 (1995) 8078
30. Yee C., Riddell S.R., and Greenberg P.D. Prospects for adoptive T cell therapy. Curr. Opin. Immunol. 9 5 (1997) 702
31. Rosenberg S.A., Yang J.C., and Restifo N.P. Cancer immunotherapy: moving beyond current vaccines. Nat. Med. 10 9 (2004) 909
32. Rosenberg S.A. Shedding light on immunotherapy for cancer. N. Engl. J. Med. 350 (2004) 1461
33. Celis E. Getting peptide vaccines to work: just a matter of quality control?. J. Clin. Invest. 110 (2002) 1765
34. Wu J., and Nandamuri K.M. Inhibition of hepatitis viral replication by siRNA. Expert. Opin. Biol. Ther. 4 10 (2004) 1649
35. Morris K.V., and Rossi J.J. Lentiviral-mediated delivery of siRNAs for antiviral therapy. Gene Ther. 13 6 (2006) 553